DaVita Q3 2022 Earnings Report
Key Takeaways
DaVita Inc. reported consolidated revenues of $2.949 billion, operating income of $312 million, and diluted earnings per share of $1.13 for the quarter ended September 30, 2022. The company repurchased 2.1 million shares of its common stock at an average cost of $87.10 per share. The third quarter was challenging due to COVID and labor pressures.
Consolidated revenues were $2.949 billion.
Operating income was $312 million and adjusted operating income was $351 million.
Diluted earnings per share was $1.13 and adjusted diluted earnings per share was $1.45.
Operating cash flow and free cash flow were $711 million and $500 million, respectively.
DaVita
DaVita
DaVita Revenue by Segment
DaVita Revenue by Geographic Location
Forward Guidance
DaVita provided adjusted operating income, adjusted diluted net income per share attributable to DaVita Inc., and free cash flow guidance for 2022.
Positive Outlook
- Absence of ballot initiative expenses: $60 million
- Integrated Kidney Care: -$25 to $0 million
- Treatment volume growth: -$200 to $0 million
- Revenue per treatment growth: $200 to $250 million
- Cost savings initiatives: $125 to $175 million
Challenges Ahead
- Labor pressure and inflation: -$300 to -$250 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income